119 related articles for article (PubMed ID: 17369192)
21. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
Guo C; Gasparian AV; Zhuang Z; Bosykh DA; Komar AA; Gudkov AV; Gurova KV
Oncogene; 2009 Feb; 28(8):1151-61. PubMed ID: 19137016
[TBL] [Abstract][Full Text] [Related]
22. Ankyrin repeat and suppressor of cytokine signaling (SOCS) box-containing protein (ASB) 15 alters differentiation of mouse C2C12 myoblasts and phosphorylation of mitogen-activated protein kinase and Akt.
McDaneld TG; Spurlock DM
J Anim Sci; 2008 Nov; 86(11):2897-902. PubMed ID: 18641171
[TBL] [Abstract][Full Text] [Related]
23. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation.
Benkerrou M; Le Deist F; de Villartay JP; Caillat-Zucman S; Rieux-Laucat F; Jabado N; Cavazzana-Calvo M; Fischer A
Eur J Immunol; 1997 Aug; 27(8):2043-7. PubMed ID: 9295043
[TBL] [Abstract][Full Text] [Related]
24. Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus.
Croker BP; Gilkeson G; Morel L
Genes Immun; 2003 Dec; 4(8):575-85. PubMed ID: 14647198
[TBL] [Abstract][Full Text] [Related]
25. PI3K/AKT, JNK, and ERK pathways are not crucial for the induction of cholesterol biosynthesis gene transcription in intestinal epithelial cells following treatment with the potato glycoalkaloid alpha-chaconine.
Mandimika T; Baykus H; Poortman J; Garza C; Kuiper H; Peijnenburg A
J Agric Food Chem; 2008 Sep; 56(18):8745-52. PubMed ID: 18729378
[TBL] [Abstract][Full Text] [Related]
26. Behavior and immune status of MRL mice in the postweaning period.
Sakić B; Szechtman H; Talangbayan H; Denburg S; Carbotte R; Denburg JA
Brain Behav Immun; 1994 Mar; 8(1):1-13. PubMed ID: 8003767
[TBL] [Abstract][Full Text] [Related]
27. The role of B cell abnormalities in the systemic autoimmune syndromes of lpr and gld mice.
Eisenberg RA; Sobel ES; Reap EA; Halpern MD; Cohen PL
Semin Immunol; 1994 Feb; 6(1):49-54. PubMed ID: 8167307
[TBL] [Abstract][Full Text] [Related]
28. Genetic dissection of SLE: SLE1 and FAS impact alternate pathways leading to lymphoproliferative autoimmunity.
Shi X; Xie C; Kreska D; Richardson JA; Mohan C
J Exp Med; 2002 Aug; 196(3):281-92. PubMed ID: 12163557
[TBL] [Abstract][Full Text] [Related]
29. Unusual expression of LINE-1 transposable element in the MRL autoimmune lymphoproliferative syndrome-prone strain.
Benihoud K; Bonardelle D; Soual-Hoebeke E; Durand-Gasselin I; Emilie D; Kiger N; Bobé P
Oncogene; 2002 Aug; 21(36):5593-600. PubMed ID: 12165858
[TBL] [Abstract][Full Text] [Related]
30. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.
Rao VK; Dowdell KC; Dale JK; Dugan F; Pesnicak L; Bi LL; Hoffmann V; Penzak S; Avila NA; Fleisher TA; Puck JM; Straus SE
Am J Hematol; 2007 Dec; 82(12):1049-55. PubMed ID: 17674358
[TBL] [Abstract][Full Text] [Related]
31. Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice.
Vidal S; Kono DH; Theofilopoulos AN
J Clin Invest; 1998 Feb; 101(3):696-702. PubMed ID: 9449705
[TBL] [Abstract][Full Text] [Related]
32. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome.
Shenoy S; Arnold S; Chatila T
J Pediatr; 2000 May; 136(5):682-7. PubMed ID: 10802504
[TBL] [Abstract][Full Text] [Related]
33. The role of noradrenergic nerves in the development of the lymphoproliferative disease in Fas-deficient, lpr/lpr mice.
del Rey A; Roggero E; Kabiersch A; Schäfer M; Besedovsky HO
J Immunol; 2006 Jun; 176(11):7079-86. PubMed ID: 16709870
[TBL] [Abstract][Full Text] [Related]
34. Role of the H-2 haplotype in Fas-intact lupus-prone MRL mice: association with autoantibodies but not renal disease.
Kong PL; Zhu T; Madaio MP; Craft J
Arthritis Rheum; 2003 Oct; 48(10):2992-5. PubMed ID: 14558109
[No Abstract] [Full Text] [Related]
35. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model.
Pan S; Mi Y; Pally C; Beerli C; Chen A; Guerini D; Hinterding K; Nuesslein-Hildesheim B; Tuntland T; Lefebvre S; Liu Y; Gao W; Chu A; Brinkmann V; Bruns C; Streiff M; Cannet C; Cooke N; Gray N
Chem Biol; 2006 Nov; 13(11):1227-34. PubMed ID: 17114004
[TBL] [Abstract][Full Text] [Related]
36. A new peak in the ALPS.
Fischer A; Rieux-Laucat F; Le Deist F
Nat Med; 1999 Aug; 5(8):876-7. PubMed ID: 10426307
[No Abstract] [Full Text] [Related]
37. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype.
Worth A; Thrasher AJ; Gaspar HB
Br J Haematol; 2006 Apr; 133(2):124-40. PubMed ID: 16611303
[TBL] [Abstract][Full Text] [Related]
38. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).
Teachey DT; Obzut DA; Axsom K; Choi JK; Goldsmith KC; Hall J; Hulitt J; Manno CS; Maris JM; Rhodin N; Sullivan KE; Brown VI; Grupp SA
Blood; 2006 Sep; 108(6):1965-71. PubMed ID: 16757690
[TBL] [Abstract][Full Text] [Related]
39. Glucocorticoid impact on cochlear function and systemic side effects in autoimmune C3.MRL-Faslpr and normal C3H/HeJ mice.
Trune DR; Kempton JB; Harrison AR; Wobig JL
Hear Res; 2007 Apr; 226(1-2):209-17. PubMed ID: 17098384
[TBL] [Abstract][Full Text] [Related]
40. Bilateral uveitis in a patient with autoimmune lymphoproliferative syndrome.
Lim WK; Ursea R; Rao K; Buggage RR; Suhler EB; Dugan F; Chan CC; Straus SE; Nussenblatt RB
Am J Ophthalmol; 2005 Mar; 139(3):562-3. PubMed ID: 15767081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
